{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-01",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Terminated",
      "city": "Toronto",
      "state": "Ontario",
      "country": "Canada",
      "classification": "Class III",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "72118",
      "recalling_firm": "Apotex Inc.",
      "address_1": "150 Signet Drive",
      "address_2": "N/A",
      "postal_code": "N/A",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Letter",
      "distribution_pattern": "Nationwide and Puerto Rico",
      "recall_number": "D1834-2015",
      "product_description": "Verapamil Hydrochloride Extended-Release tablets, USP, 240 mg, 500-count bottles, Rx Only, Apotex Corp. Manufactured by Apotex Research Private Limited, Bangalore, Karnataka 560 099, India; Manufactured for: Apotex Corp., Weston, FL 33326. NDC 60505-2742-5.",
      "product_quantity": "2,075 bottles",
      "reason_for_recall": "Failed Dissolution Specification: One lot of product did not meet the first stage dissolution specification limits.",
      "recall_initiation_date": "20150721",
      "center_classification_date": "20150930",
      "termination_date": "20170215",
      "report_date": "20151007",
      "code_info": "Lot #: KP2621, Exp 8/2015"
    }
  ]
}